For ongoing clinical trials, we searched in the clinicaltrials.gov database for recruiting and active, not recruiting trials, using the following keywords: “metastatic prostate cancer”, or, “metastatic castration-resistant prostate cancer”, and, “antibody drugs conjugates”, or, “STEAP-1”, or, “TROP2”, or, “PSMA, or, “CD46”, or, “B7-H3”. Here, TACSTD2 is linked to prostate carcinoma.